JPMorgan analyst Eric Joseph initiated coverage of Bluebird Bio with an Overweight rating and $7 price target. With two transgenic cell therapy launches underway, and a third possible by year end, Bluebird is well positioned in the emerging class of autologous cell therapies for inherited hematological disorders, the analyst tells investors in a research note. The firm says feedback from its physician survey supports "compelling latent demand" for the modality in treating sickle cell disease, with specific views on Bluebird Bio’s lovo-cel supporting its "competitive if not best-in-class" positioning.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BLUE:
- bluebird bio Down Even after BLA Submission for Sickle Cell Disease Gene Therapy
- Bluebird Bio submits BLA for lovo-cel gene therapy for SCD treatments
- Bluebird Bio price target lowered to $6 from $8 at BofA
- Bluebird Bio reaction to lovo-cel BLA delay ‘overdone,’ says Raymond James
- BLUE Turns Red on Q4 Miss and Delay in Gene Therapy Application
